These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33593595)

  • 21. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal.
    Santos IF; Pereira S; McLeod E; Guillermin AL; Chatzitheofilou I
    Acta Med Port; 2014; 27(5):615-24. PubMed ID: 25409218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
    Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
    Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rivaroxaban starter packs on emergency department throughput.
    Ayers GT; D'Amico PhD F; Farrah RM; Klatt PM; Baumgartner MA
    Am J Emerg Med; 2018 Sep; 36(9):1698-1699. PubMed ID: 29429797
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of venous thromboembolism in a 22-year-old woman taking an oral contraceptive pill.
    Shafran DM; Wu C
    CMAJ; 2017 Nov; 189(47):E1459-E1460. PubMed ID: 29180385
    [No Abstract]   [Full Text] [Related]  

  • 31. UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST Registry.
    Speed V; Patel JP; Roberts LN; Patel RK; Arya R;
    Thromb Res; 2021 Jan; 197():16-19. PubMed ID: 33160116
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
    Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
    Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children.
    Male C; Monagle P; Albisetti M; Brandão LR; Young G
    J Pediatr; 2022 Jan; 240():14-23. PubMed ID: 34687696
    [No Abstract]   [Full Text] [Related]  

  • 34. Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
    Mantovani LG; Haas S; Kreutz R; Folkerts K; Gebel M; Monje D; Schneider J; van Eickels M; Sahin K; Zell E; Ageno W; Turpie AGG
    Eur J Intern Med; 2019 Mar; 61():29-33. PubMed ID: 30342973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
    Sciascia S; Breen K; Hunt BJ
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
    [No Abstract]   [Full Text] [Related]  

  • 36. [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
    Pernod G; Elias A; Gouin I; Gaillard C; Nguyen P; Ouvry P; Sié P
    J Mal Vasc; 2012 Dec; 37(6):300-10. PubMed ID: 23122646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
    Yang VK; Cunningham SM; Rush JE; de Laforcade A
    J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):729-36. PubMed ID: 26990131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
    Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.